# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through ...
New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be...
Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $...
EDBL: 87% | Edible Garden shares are trading higher. The company reported Q1 financial results. MNDY: 22% | Monday.com shares ...